About Us | Contact Us |        

Best Practices in Prostacyclin Therapy for Pulmonary Arterial Hypertension in the Hospitalized Patient

Critical Care
Identifying Pulmonary Arterial Hypertension in the Hospitalized Patient
0.5 AMA PRA Category 1 Credit(s)
Launch Date:
December 13, 2018
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Hospitalists, Internal Medicine

Relevant Terms:

Cardiology, Pulmonary Medicine

Ronald J. Oudiz, MD

Ronald J. Oudiz, MD
Professor of Medicine 
David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension LA BioMed Research Institute at Harbor-UCLA Medical Center

Ronald J. Oudiz, MD, is a Professor of Medicine and the Director of the Pulmonary Hypertension Center at the David Geffen School of Medicine at UCLA, and is a Faculty Cardiologist at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Southern California. He received his Medical School training at the University of Southern California in Los Angeles, his Internal Medicine training at the University of California, San Diego, and his training in Cardiovascular Diseases at Harbor-UCLA Medical Center in Torrance, CA, USA. Dr Oudiz is board-certified in Internal Medicine and Cardiovascular Diseases. He is a past holder of scientific research awards from the American Heart Association and the National Institutes of Health, received the Pulmonary Hypertension Association (PHA) Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care in 2011, and was a 2015 PHA Legacy Award Recipient. He is the Chair-Elect of the PHA Scientific Leadership Council. Dr. Oudiz has authored several papers in pulmonary hypertension and has presented his research at national and international seminars. He is a past Editor-in- Chief of the scientific publication Advances in Pulmonary Hypertension, and immediate past chair of the Pulmonary Vascular NetWork, American College of Chest Physicians. Dr. Oudiz has participated in several trials of innovative medical treatments for pulmonary hypertension, many of which are still ongoing. His research focus has been to describe the physiologic abnormalities that are caused by PH using measurements of lung gas exchange during exercise, and to study exercise rehabilitation as a treatment modality for patients with pulmonary hypertension.

Timothy M. Fernandes, MD, MPH

Timothy M. Fernandes, MD, MPH
Associate Clinical Professor of Medicine
University of California, San Diego
Division of Pulmonary and Critical Care Medicine
Pulmonary Vascular Program
San Diego, CA

Timothy Fernandes, MD, MPH, is a board-certified pulmonologist who focuses on pulmonary vascular disease. He has a special interest in caring for patients who have venous thromboembolism, pulmonary arterial hypertension, and chronic thromboembolic pulmonary hypertension. Dr. Fernandes is active in clinical research investigating the progression of acute pulmonary embolism to chronic thromboembolic disease (CTEPH), and patient outcomes following pulmonary endarterectomy (PTE) surgery. He has been awarded the CHEST Foundation Clinical Research Grant in Pulmonary Arterial Hypertension, and the Thrombosis and Hemostasis Summit of North America Travel Award. Dr. Fernandes completed his fellowship training at UC San Diego School of Medicine and his residency at Case Western Reserve University School of Medicine, where he served as chief medical resident. He earned his medical degree at University of Cincinnati College of Medicine. Dr. Fernandes is board-certified in critical care medicine, pulmonary disease and internal medicine and is a fellow of the College of Chest Physicians."

1. Assess the clinical trial data, safety, and efficacy of prostacyclin therapies for the management of pulmonary arterial hypertension (PAH).
2. Review the role of the hospitalist in the selection, administration, monitoring, and evaluation of side effects of therapies for pulmonary arterial hypertension (PAH).
3. Identify strategies for collaborative care with specialty centers when managing hospitalized patients with pulmonary arterial hypertension (PAH).

CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare
AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
Method of Participation Statements of credit will be awarded based on the participant reviewing the entire presentation, scoring a 70% on the post test, and completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com
Faculty Disclosures
Dr. Fernandez has disclosed the following relevant financial relationships:
Consultant - Actelion
Speakers Bureau - Bayer

Dr. Oudiz has disclosed the following relevant financial relationships:
Consultant - Actelion, Arena, Bayer, Gilead, United Therapeutics
Contract Research - AADi, Actelion, Arena, Bayer, Gilead, Liquidia, Reata, United Therapeutics
Speakers Bureau - Actelion, Bayer, Gilead, United Therapeutics

Accredited Provider Disclosure
Margaret V. Clark, MSc, RN, RRT - NPS, CMPP, Medical Writer/Interviewer, discloses no financial relationships with pharmaceutical or medical product manufacturers.
Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner, discloses no financial relationships with pharmaceutical or medical product manufacturers.
Patricia Brignoni, AKH Director of Operations: has disclosed no relevant financial relationships.

Steve Eckert, AKH President & CEO, Planner: has disclosed no relevant financial relationships.
AKH Inc, planners and reviewers have disclosed no financial relationships with pharmaceutical or medical product manufacturers.
Commercial Support 
This activity is supported by an educational grant from Actelion Pharmaceuticals.
There is no fee to participate in this activity
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure Declaration
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
Copyright © 2018 No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publishe
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.